XEN1101 + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Generalized Tonic-Clonic Seizures
Conditions
Primary Generalized Tonic-Clonic Seizures
Trial Timeline
Feb 14, 2023 → Jun 1, 2027
NCT ID
NCT05667142About XEN1101 + Placebo
XEN1101 + Placebo is a phase 3 stage product being developed by Xenon Pharmaceuticals for Primary Generalized Tonic-Clonic Seizures. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05667142. Target conditions include Primary Generalized Tonic-Clonic Seizures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05716100 | Phase 3 | Recruiting |
| NCT05667142 | Phase 3 | Recruiting |
| NCT05614063 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Generalized Tonic-Clonic Seizures